Picture this: you own a small company, you spend years and hundreds of millions of dollars developing a drug for a rare disease that kills children. Somewhere along the way, the regulator — in this case, the FDA — tells you: "Go ahead with this type of study, we'll accept it." You go ahead. You spend more. You show up at the door with data in hand. And the regulator says: "Nah, now we want something else."

Welcome to the American regulatory circus of 2026.

What's Going On

Over the past twelve months, the FDA has denied or discouraged the submission of at least eight new drugs, according to a review by RTW Investments. The list is brutal:

  • UniQure: gene therapy for Huntington's disease — rejected.
  • Regenxbio: gene therapy for Hunter Syndrome — blocked.
  • Disc Medicine: drug for a blood condition — denied.
  • Moderna: their own flu vaccine was initially refused for review (they later reversed course, but the market damage was already done).

In every case, the FDA questioned the quality of the evidence presented. Some studies didn't test the drug against a placebo. Others used biomarkers instead of directly measuring clinical efficacy.

Fair enough. Scientific rigor matters. The problem? The companies themselves say they followed the FDA's prior guidance.

The UniQure Case Is Textbook

UniQure says the FDA had agreed the company could seek approval using comparative data from an external database of Huntington's patients — no randomized placebo-controlled study needed. Now the agency has backtracked and demanded a new head-to-head comparative study.

A former FDA official spoke to CNBC on condition of anonymity and called it what it is: "the worst kind of regulatory uncertainty." Companies receive guidance, invest based on it, and then find out the rules of the game changed mid-play.

The FDA's official response? A boilerplate statement saying there is "no regulatory uncertainty" and that the agency "makes evidence-based decisions but does not guarantee outcomes."

Are you kidding me? That's like a referee saying there's no confusion in the game while changing the rules every quarter.

The Domino Effect on the Market

The fear now is that this stricter — or more erratic, depending on how you see it — stance will hit other companies with drugs in the pipeline. Analysts are watching:

  • Dyne Therapeutics (Duchenne muscular dystrophy)
  • Taysha Gene Therapies (Rett syndrome)
  • Wave Life Sciences (liver condition)
  • Lexeo Therapeutics (Friedreich's ataxia)

All of these stocks are in the red in 2026. And it's no coincidence.

Luca Issi, analyst at RBC Capital Markets, put it well: "What investors and stakeholders want to see is consistency. And right now, that seems to be lacking."

Dyne tried to calm the market by saying it maintains "frequent, positive, and collaborative dialogue" with the FDA. Taysha, Wave, and Lexeo declined to comment. When a company would rather stay quiet, the silence usually speaks louder than any press release.

The Real Dilemma Behind the Headlines

There's a legitimate debate here. In recent years, the FDA was more flexible with drugs for rare diseases, accepting studies less rigorous than the gold standard (randomized, double-blind, placebo-controlled trials). The logic was sound: patients with degenerative diseases don't have time to wait ten years for a perfect study. Every month lost can mean loss of mobility, speech, or life.

But critics argued that this flexibility brought false hope. Drugs approved on weak evidence might not actually work.

The problem isn't the FDA wanting to be more rigorous. The problem is changing the standard without warning, after companies have already spent fortunes following prior guidance. That's the opposite of smart regulation. That's a regulatory trap.

As Taleb would say: if the regulator has no skin in the game — if they pay no price when they change their mind — the ones who suffer are the patients and investors who trusted the process.

FDA Commissioner Marty Makary publicly promised flexibility for rare diseases. Sounds great in a speech. In practice, the past few months tell a different story.

So here's the question no bank analyst is going to ask you: if the agency itself doesn't follow the rules it set, what's the real risk premium for investing in biotech today?